Federal Trade Commission staff are sending warning letters to 25 companies that market healthcare plans or generate sales leads for them, the agency said on October 29, 2026, with the enrollment season for health coverage under way. The letters accuse no recipient of wrongdoing. They do list the coverage, cost and incentive claims the FTC regards as likely deceptive, restate the federal bans on prerecorded sales calls and on impersonating government agencies or insurers, and point out that breaking either rule can carry a civil penalty of up to $53,088 per violation. More letters will go out on a rolling basis, according to the FTC.

In Short

The FTC wrote to 25 companies that sell health plans, or that collect the names and phone numbers of people shopping for them, and told them not to lie about what a plan covers, what it costs or who is behind it. This matters because these companies find customers through online ads, websites and phone calls during the weeks when people pick a plan, and some past offenders sold cheap discount cards dressed up as real insurance. The letters do not say any of the 25 broke the law, but they make clear that robocalls, fake government branding and misleading coverage claims can lead to court orders, refunds and fines of up to $53,088 for each violation.

What the FTC sent

The release runs to a few hundred words. The letter behind it is longer and more specific. Under the headline "FTC Staff Warn Marketers of Healthcare Plans and Lead Generators Not to Deceive Consumers about the Terms of the Advertised Plans," the agency opened with timing: "With open enrollment season for healthcare plans in progress, Federal Trade Commission staff are sending warning letters to 25 companies that market or generate sales leads for healthcare plans."

The targets are defined broadly. According to the FTC, the letters are going to companies "that market or advertise Affordable Care Act Marketplace health insurance or other healthcare products, such as limited indemnity plans and medical discount programs." The release adds that "the agency expects to send additional letters on a rolling basis," so 25 is a starting count rather than a final one.

None of the 25 is named. The FTC's warning-letter listing tied to the October 29 release carries a single entry: a template titled "Warning Letter Template Regarding Deceptive or Unfair Acts or Practices Relating to the Marketing, Advertising, and Lead Generation of Healthcare-Related Products, Including Healthcare Plans." The template leaves the date, recipient name and address blank. It is signed by Lois C. Greisman, Associate Director of the Division of Marketing Practices in the Bureau of Consumer Protection, it is marked for delivery by Federal Express, and it directs questions to Thomas M. Biesty of the FTC.

The bureau's director supplied the only quote. "Making healthcare more transparent and affordable is a top priority for the FTC," said Christopher Mufarrige, Director of the FTC's Bureau of Consumer Protection. "Americans experiencing rising healthcare costs should not also have to worry about whether a healthcare plan or program is what it claims to be. The FTC will remain focused on monitoring this market and will not hesitate to hold accountable companies that unlawfully market or advertise healthcare plans to consumers. Today's letters remind companies that open enrollment is not an invitation to misrepresent what their plans actually cover."

Mufarrige's name has been on a run of advertising cases this year, from the FTC's January complaint that JustAnswer advertised $1 or $5 trials while charging monthly fees of $28 to $125 to the $35 million Hopper settlement over hidden booking fees in July.

Four kinds of claims

The legal hook is Section 5(a) of the FTC Act, which bans deceptive or unfair acts or practices in commerce. The letter is direct about where its list comes from: "Based on information collected by FTC staff and the Commission's enforcement experience in this area, we have identified a pattern of deceptive claims made by marketers or advertisers, including lead generators, of health insurance and healthcare-related products." It adds that "such claims have been the subject of consumer complaints."

Four categories follow, in the letter's words:

  • Benefits: "misrepresenting the benefits included in a healthcare-related product, including any insurance benefits"
  • Comprehensive coverage: "misrepresenting that a healthcare-related product is major or comprehensive medical health insurance or the equivalent of such health insurance"
  • Costs: "misrepresenting the costs of healthcare-related products"
  • Incentives: "falsely claiming that consumers who enroll in a healthcare-related product will receive free offers, cash rewards, rebates, or other incentives"

The list says "include, but are not limited to," so it is a floor. The fourth item reads most directly onto advertising creative. A promised reward for enrolling is a statement made in the ad itself, and the letter treats a false version of it as a deception in its own right, separate from anything said about the coverage.

Wording that shifted between the release and the letter

The two documents describe the same list, but not in identical terms. The release talks about a "healthcare plan" throughout, while the letter uses "healthcare-related product," which is wider and covers discount programs that are not plans in any insurance sense. The release's first category adds a word: "Misrepresenting the benefits or limitations of a healthcare plan." Its second category adds a clause, "when in fact it is not." And where the release gives "limited indemnity plans" as an example of the products in scope, the letter refers to "limited benefit plans or medical discount programs."

None of these differences changes the substance. Taken together, they show the letter is the legal instrument and the release a summary of it, so the letter's wider "healthcare-related product" language is the one that defines whom the warning reaches.

Robocalls and the Do Not Call Registry

The release says nothing about phone calls. The letter devotes a paragraph to them. "Consumers have also reported receiving unsolicited calls promoting healthcare-related product offers," it says, before turning to the Telemarketing Sales Rule, 16 C.F.R. § 310.4(b)(1).

The rule, according to the letter, prohibits sellers and marketers "from initiating or causing the initiation of outbound telephone calls that deliver pre-recorded messages" to induce the purchase of products, health insurance included. The phrase "causing the initiation" matters for lead generators. On that wording, a company that never dials a number can still sit inside the prohibition if it sets off the calls. Several of the FTC's own cases describe exactly that arrangement, in which a lead collected on a website is sold to a call center.

The letter also restates the registry rule: "The TSR also prohibits calling consumers who have placed their phone number on the National Do Not Call Registry, absent consent or other narrow exceptions." Access to that registry got more expensive this autumn. From October 1, 2026, telemarketers pay $85 per area code a year, up from $82, with a maximum of $23,425 for any single entity.

The TSR is the FTC's regime. Calls are also governed by the Telephone Consumer Protection Act, which the FCC administers, and that framework is in flux: on February 25, 2026, the Fifth Circuit ruled that oral consent satisfies the statute for prerecorded and autodialed calls to wireless numbers, in conflict with the FCC's written-consent requirement for telemarketing. The October 29 letters cite only the FTC rule.

Consumer frustration with such calls shows up in survey data. A survey of 1,000 US consumers by Cloaked, published in July, found an average of 16 spam calls and nine spam texts a month, robocalls as the top frustration for 58% of respondents, and 41% registered with the Do Not Call list.

Impersonating HHS and insurers

The third legal pillar is the Rule on Impersonation of Government and Business, 16 C.F.R. Part 461. According to the letter, it "makes it illegal to falsely pose as a government agency (such as the Department of Health and Human Services) or business entities (such as insurance carriers), or to misrepresent affiliation with, endorsement, or sponsorship by, a government agency or business entities, including entities that offer health insurance policies under the Affordable Care Act."

That rule took effect in April 2024, when FTC data put impersonation reports for 2023 near 500,000 and losses above $1.1 billion. Its relevance to health insurance shows up in the FTC's own recent work. In the agency's annual report on older consumers, released on October 19, phone scam reports in which older adults lost no money often involved impersonations of Medicare, banks, Amazon and the FTC itself.

Platforms drew a similar line earlier. Google strengthened its misrepresentation policy against ads that impersonate public figures, brands or organizations, or falsely imply affiliation or endorsement, with enforcement from March 2024 and immediate account suspension for violators. The letter puts a federal penalty behind conduct that, for search advertisers, was already a suspension risk.

Penalties and remedies

The letter's tone hardens at this point. "Violations of the FTC Act and the rules identified above carry serious legal and financial consequences," it says. "Such violations may result in a federal court injunction halting your business operations."

The money comes in two forms. First, according to the letter, "companies or individuals that violate either rule may be subject to a civil penalty of up to $53,088 per violation, and each unlawful call, advertisement, or misrepresentation may constitute a separate violation." "Either rule" refers to the Telemarketing Sales Rule and the Impersonation Rule. Second, violators may be required to pay refunds to consumers or provide other relief under Section 19(b) of the FTC Act.

The per-violation structure is what gives the figure weight. A single prerecorded campaign of 1,000 unlawful calls, priced at the maximum, would reach $53.1 million, a PPC Land calculation on the letter's ceiling rather than a figure the FTC uses. The letter says violators "may be subject to" the penalty, which makes $53,088 a cap, not a tariff.

The remedies named are all federal court remedies. That fits the agency's current position. In March, the Fifth Circuit vacated the FTC's in-house order against Intuit's TurboTax advertising and held that deceptive-advertising claims must be decided by an Article III court, at least in Texas, Louisiana and Mississippi. The two healthcare cases the FTC brought in 2026 were both filed in federal court in the Southern District of Florida.

Ads, websites and affiliates

The review the letter asks for runs past a company's own creative to the affiliates, distributors and agents selling on its behalf. In the letter's words, the FTC encourages each recipient "to conduct a comprehensive review of your marketing and advertising practices" covering "paid or other online ads, representations made on your websites, on social media, in promotional materials and communications, and through third-party distributors, marketing affiliates, and sales agents."

For agencies and in-house teams working in search engine marketing, that sentence is the core of the document. Paid ads, websites and social placements are listed by name, and so are representations made through third parties. The letter does not say a company is liable for every affiliate claim. It does make the affiliate channel part of the review the FTC expects.

The closing paragraphs lower the temperature and then raise it again. "This letter is not intended to reflect an assessment or conclusion by the FTC staff that you or your company have engaged in illegal conduct," it says. "We are sending similar letters to other companies engaged in marketing and lead generation related to health insurance and healthcare-related products." It also states that the list of laws is not exhaustive, that compliance is the recipient's responsibility, and that "FTC staff will continue to actively monitor this market for potentially deceptive or unfair acts or practices and will take enforcement action as warranted."

What the letter does not contain is just as telling. It sets no response deadline, asks for no reply, and requests no documents. It is a notice, not an investigation.

Eight cases on the record

The letter cites eight FTC cases that, in its words, "demonstrate the Commission's focus on protecting consumers from such unlawful conduct." The release names seven, because it groups Assurance IQ and MediaAlpha, which the FTC announced together in August 2025.

Two 2026 cases still in court

Top Healthcare Options Insurance Agency (S.D. Fla., No. 0:26-cv-60067-SMITH) is in active litigation. According to the letter, the FTC alleges the defendants falsely represented that limited benefit and medical discount plans were comprehensive health insurance, and the court has issued a preliminary injunction. The FTC announced in January that, at its request, the court had halted the operations of nine companies and three individuals. According to the FTC's complaint as described in that announcement, consumers entered their details on websites promoting Affordable Care Act and Obamacare plans that were in fact built for lead generators, which sold the information to the defendants or their vendors for telemarketing. The agency put the harm in the tens of millions of dollars. The defendants include Elevation Media Group, Ramz Media Marketing and Sargent Financial, which does business as WeMake Media.

Innovative Partners (S.D. Fla., No. 26-60976-CIV-SINGHAL) is also ongoing, with a preliminary injunction entered. The FTC alleges the defendants "impersonated the government and insurance carriers to deceive consumers into purchasing healthcare-related products falsely advertised as comprehensive health insurance," according to the letter. In its April 2026 announcement the FTC said the six defendants sold supposed PPO plans that were neither PPO plans nor comprehensive insurance, and charged them with violating the FTC Act, the Telemarketing Sales Rule, the Impersonation Rule and the Gramm-Leach-Bliley Act.

Settlements and judgments

  • Assurance IQ (W.D. Wash., No. 2:25-cv-01485-MJP): a 2025 order requiring $100 million in consumer redress, in a case alleging deceptive telemarketing of plans that did not provide the comprehensive coverage advertised.
  • MediaAlpha (C.D. Cal., No. 2:25-cv-07263): a 2025 order requiring the lead generators to pay $45 million and barring deceptive claims about government affiliation, fake endorsements, health coverage and cost. The case alleged "use of deceptive ads and websites to collect consumer information that was sold to telemarketers of healthcare plans," according to the letter. When the FTC announced the settlement on August 7, 2025, it said MediaAlpha sold roughly 119 million leads in 2024, used domains such as ObamacarePlans.com, and ran ads in which actors and celebrities promoted a government give-back program that did not exist.
  • Simple Health Plans (S.D. Fla., No. 18-cv-62593): a 2024 order imposing a $195 million judgment against lead generators and telemarketers alleged to have sold medical discount and limited benefit programs as comprehensive insurance.
  • Consumer Health Benefits Association (E.D.N.Y., No. 1:10-cv-03551): a 2023 order requiring telemarketers to pay $7 million in redress over medical discount plans allegedly pitched as affiliated with state-sanctioned programs or qualified Affordable Care Act plans. The FTC links this case to an announcement from August 2010, so the order came some 13 years after the case began.
  • Benefytt Technologies (M.D. Fla., No. 8:22-cv-01794): 2022 orders requiring $100 million in redress and banning two executives from marketing or selling healthcare-related products, in a case alleging deceptive lead generation and sales practices, including bundling and unfair fees for unwanted products.
  • Partners in Healthcare Association (S.D. Fla., No. 1:14-cv-23109): a 2016 order barring defendants alleged to have marketed medical discount plans as health insurance from selling healthcare-related products and from telemarketing, with an $8.7 million judgment. The release links this case to an FTC announcement dated November 2015.

What the figures add up to

The monetary amounts in the six resolved cases total $455.7 million, a PPC Land sum of the figures as the letter states them. The total mixes redress orders with judgments, and a judgment is not the same as money collected, so it measures what courts ordered, not what consumers received. The two 2026 cases carry no amount yet.

The span is also telling. The oldest case on the list dates to 2010, the newest to April 2026, and the central allegation recurs across those 16 years: discount cards and limited plans sold as if they were comprehensive cover, often through calls fed by leads.

A second round in under two years

This is not the first time the FTC has written to this industry. On December 10, 2024, the agency announced warning letters to 21 healthcare plan marketers and lead generators. That round was announced by Samuel Levine, then Director of the Bureau of Consumer Protection, and it listed the same four categories of claims: benefits, comprehensive coverage, costs, and false promises of free offers, cash rewards, rebates or other incentives. That release also said the letters did not allege any wrongdoing.

The October 2026 round goes to four more companies, comes under a different administration and a different bureau director, and promises additional letters as the season continues. The 2026 letter necessarily cites cases that postdate the first round, including Assurance IQ, MediaAlpha and the two Florida cases filed this year. The four-category list itself has been carried across almost unchanged, which points to continuity in the program rather than a new theory.

It also fits the agency's declared priorities. The FTC's 2026-2030 strategic plan, published in April, named health fraud alongside opioid recovery fraud and privacy and data security violations as priority areas.

Open enrollment and the paid search problem

The release describes open enrollment as already in progress on October 29. The FTC's consumer alert published the same day dates the Health Insurance Marketplace window from November 1 to January 15. That alert tells consumers the agency has written to marketers, flags potential scam ads in paid search results and on social media, and reminds readers that robocalls with prerecorded messages marketing health insurance are illegal.

An earlier FTC consumer alert, dated September 28, went further on search. It warned that scammers and dishonest businesses sometimes pay to appear at the top of search results, told consumers to look for Ad or Sponsored labels, and pointed them to Medicare.gov and HealthCare.gov as the starting point. The agency's consumer guidance, in effect, tells shoppers to treat paid placements with suspicion during open enrollment.

Search inventory for health advertisers is also changing. Google has been testing healthcare ads in AI Mode and AI Overviews in the US, a test confirmed during Google Marketing Live in May 2026 and limited to English queries. Health insurance was not singled out in that test.

Why this matters for marketers

Health insurance lead generation sits where several regulated activities meet: paid media buying, landing pages that collect personal data, resale of that data, and outbound calling. The FTC's cases show the agency follows the chain from the ad to the call. In MediaAlpha, the complaint centered on ads and websites; in Top Healthcare Options, on websites built for lead generators; in Assurance IQ, on the telemarketing at the end of the funnel.

The letters do not create new law. Every rule they cite was in force before October 29, and the four claim categories match the 2024 list. What changes is notice. Each recipient now has the FTC's view in writing, and the template states plainly that the agency is "sending similar letters to other companies" in the sector.

For media buyers and agencies, the practical exposure lies in the parts of the letter about paid ads, affiliates and calls caused rather than made. A lead seller whose buyers run prerecorded calls, or an affiliate network whose publishers use government-style branding, falls within the territory the letter describes. Whether the FTC brings cases against any of the 25 recipients, or against companies that get the next batch, will show how much weight the warnings carry.

Timeline

Summary

Who: Federal Trade Commission staff in the Bureau of Consumer Protection's Division of Marketing Practices, with a letter signed by Associate Director Lois C. Greisman and a statement from bureau Director Christopher Mufarrige. The recipients are 25 unnamed companies that market or generate sales leads for Affordable Care Act Marketplace insurance and other healthcare products such as limited plans and medical discount programs.

What: Warning letters that list four categories of likely deceptive claims (benefits, comprehensive coverage, costs, and false incentives), restate the Telemarketing Sales Rule's bans on prerecorded sales calls and calls to Do Not Call numbers, restate the Impersonation Rule, and set out penalties of up to $53,088 per violation plus injunctions and refunds. The letters cite eight FTC cases and ask recipients to review paid online ads, websites, social media and affiliate marketing.

When: The FTC announced the letters and published the template on October 29, 2026, days before Health Insurance Marketplace open enrollment began on November 1. More letters will follow on a rolling basis.

Where: The United States. The two 2026 cases the letters cite are in federal court in the Southern District of Florida.

Why: According to the FTC, information collected by staff and its enforcement experience show a pattern of deceptive claims by marketers and lead generators of health insurance and healthcare-related products, many of them the subject of consumer complaints. The letters put the industry on notice during the period when consumers choose coverage.